» Articles » PMID: 9954

The Effects of Atenolol (tenormin) and Methyldopa on Simple Tests of Central Nervous Function

Overview
Specialty Pharmacology
Date 1975 Dec 1
PMID 9954
Citations 10
Authors
Affiliations
Soon will be listed here.
Abstract

Two identical studies, one comparing the effect of single doses of a new beta-adrenoceptor blocker, atenolol (Tenormin) (50 mg and 100 mg) and placebo, and the other comparing the effect of single doses of methyldopa (250 mg and 500 mg) and placebo, in healthy volunteers, were carried out. 2 In both studies the effect of the drugs upon reaction time, critical flicker frequency, subjective drowsiness, pulse rate and blood pressure was measured. 3 Atenolol produced no effect upon reaction time, critical flicker frequency or subjective feelings, while methyldopa produced a statistically significant prolongation of reaction time and a statistically significant increase in the subjective sensation of drowsiness. 4 Atenolol produced statistically significant reductions in systolic and diastolic blood pressure and in pulse rate while methyldopa was without effect. 5 It is concluded that atenolol is unlikely to produce the side effects of sedation or drowsiness.

Citing Articles

Time course of blood pressure, pulse rate, plasma renin and metoprolol during treatment of hypertensive patients.

Haglund K, Collste P Eur J Clin Pharmacol. 1980; 17(5):321-8.

PMID: 6998708 DOI: 10.1007/BF00558443.


Effect of guanfacine on vigilance.

HEIDBREDER E, Pagel G, Roeckel A, Heidland A Br J Clin Pharmacol. 1980; 10 Suppl 1:169S-172S.

PMID: 6994772 PMC: 1430115. DOI: 10.1111/j.1365-2125.1980.tb04926.x.


Smoking, pain tolerance, and physiological activation.

Waller D, SCHALLING D, Levander S, Edman G Psychopharmacology (Berl). 1983; 79(2-3):193-8.

PMID: 6133303 DOI: 10.1007/BF00427811.


Guanfacine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the treatment of hypertension.

Sorkin E, Heel R Drugs. 1986; 31(4):301-36.

PMID: 3519177 DOI: 10.2165/00003495-198631040-00003.


Central effects of beta-adrenoceptor antagonists. I--Performance and subjective assessments of mood.

Currie D, Lewis R, McDevitt D, Nicholson A, Wright N Br J Clin Pharmacol. 1988; 26(2):121-8.

PMID: 2905148 PMC: 1386519. DOI: 10.1111/j.1365-2125.1988.tb03378.x.


References
1.
Hamilton M, KOPELMAN H . Treatment of severe hypertension with methyldopa. Br Med J. 1963; 1(5324):151-5. PMC: 2123398. DOI: 10.1136/bmj.1.5324.151. View

2.
Prichard B . HYPOTENSIVE ACTION OF PRONETHALOL. Br Med J. 1964; 1(5392):1227-8. PMC: 1814361. DOI: 10.1136/bmj.1.5392.1227. View

3.
Prichard B, Johnston A, Hill I, ROSENHEIM M . Bethanidine, Guanethidine, and Methyldopa in Treatment of Hypertension: a Within-patient Comparison. Br Med J. 2010; 1(5585):135-44. PMC: 1984601. DOI: 10.1136/bmj.1.5585.135. View

4.
Hansson L, Aberg H, Jameson S, Karlberg B, MALMCRONA R . Initial clinical experience with I.C.I. 66.082, a new beta-adrenergic blocking agent, in hypertension. Acta Med Scand. 1973; 194(6):549-50. DOI: 10.1111/j.0954-6820.1973.tb19489.x. View

5.
Simpson F . Beta-adrenergic receptor blocking drugs in hypertension. Drugs. 1974; 7(1):85-105. DOI: 10.2165/00003495-197407010-00006. View